Treadwell Therapeutics, a clinical-stage biotechnology company developing novel, cross-modality medicines for unmet needs in cancer, announced on November 18 the closing of an oversubscribed Series B financing, which raised more than $91 million.
Proceeds will fund the continued clinical development of CFI-400945, CFI-402257 and CFI-402411, the preclinical development of the Biologics and Cell Therapy platform. Financing led by Sino Biopharmaceutical and 3W Fund and includes other healthcare focused funds.
Treadwell Therapeutics presented at the 2021 OBIO Investment Summit.